On September 9, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sevabertinib for the treatment of patients with locally advanced or metastatic non-squamous non–small cell lung cancer (NSCLC). This decision marks a significant advancement in the therapeutic options available for this patient population.

Sevabertinib's approval under an accelerated pathway highlights its potential to address unmet medical needs in lung cancer care. Healthcare professionals, particularly oncologists, should consider this development when evaluating treatment plans for appropriate patients.

The FDA's regulatory action reflects ongoing efforts to facilitate access to promising therapies based on preliminary evidence. Continued clinical evaluation will be essential to further define sevabertinib's role and long-term benefits in NSCLC treatment.